文献速递主动脉疾病

TRANSFIX研究更新结果:Zenith Alpha胸主动脉支架治疗钝性胸主动脉损伤

Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device.
PubMed 文献 · J Vasc Surg · 2020-02-01

TRANSFIX是一项在美国17家中心开展的前瞻性、多中心、非随机、单臂IDE研究,评估Zenith Alpha胸主动脉内移植物治疗钝性胸主动脉损伤(BTAI)的安全性和有效性。15例(30%)患者发现移植物内血栓,无临床后遗症,但制造商因此自愿移除了该设备的BTAI适应症。

要点

  • 2年主动脉损伤愈合率达96%,但30%患者发现移植物内血栓,无临床后遗症。
  • 制造商已自愿移除该设备的BTAI适应症,需谨慎选择尺寸并终身随访。

核心结论

  • TRANSFIX研究更新结果显示,Zenith Alpha胸主动脉支架治疗BTAI的主动脉损伤相关死亡率和主要不良事件发生率低。
  • 但移植物内血栓的发现导致制造商自愿移除了该设备的BTAI适应症。
  • 应谨慎进行设备尺寸选择和规划(如限制移植物oversizing),并定期终身随访。

研究设计与样本

  • 前瞻性、多中心、非随机、单臂IDE研究,在美国17家中心开展。
  • 共纳入50例BTAI患者,2013年1月至2014年5月入组。
  • 平均随访21个月(范围0.6-35个月)。

主要发现

  • 30天死亡率为2%(n=1),与主动脉修复或研究设备无关。
  • 30天后发生5例死亡,其中1例认为与手术相关。
  • 2年主动脉损伤愈合率为96%。
  • 15例(30%)发现移植物内血栓(核心实验室12例,中心3例),13例(26%)确认,最近随访无临床后遗症。

关键数值与推荐

  • 主要安全终点为30天全因死亡率和主动脉损伤相关死亡率。
  • 主要有效性终点为30天设备成功率。
  • 额外结局包括主要不良事件和影像学发现(主动脉损伤愈合、移植物通畅性和设备完整性),通过5年随访CT由核心实验室分析。

临床怎么用

  • Zenith Alpha胸主动脉支架治疗BTAI的主动脉损伤相关死亡率和主要不良事件发生率低。
  • 制造商已自愿移除该设备的BTAI适应症。
  • 应谨慎进行设备尺寸选择和规划(如限制移植物oversizing),并定期终身随访。

局限性

  • 单臂、非随机研究,样本量较小(50例)。
  • 平均随访时间较短(21个月),部分患者随访不足5年。
  • 移植物内血栓的临床意义尚不明确,需长期随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this study was to report the updated results of a prospective, multicenter, nonrandomized, single-arm investigational device exemption study conducted at 17 sites in the United States to assess safety and effectiveness of the Zenith Alpha thoracic endovascular graft (Cook Medical, Bloomington, Ind) for treatment of blunt thoracic aortic injury (BTAI). METHODS: The primary safety end point was 30-day all-cause mortality and aortic injury-related mortality. The primary effectiveness end point was 30-day device success. Additional outcomes evaluated included major adverse events and imaging findings including aortic injury healing, graft patency, and device integrity as analyzed by the core laboratory on follow-up computed tomography imaging through 5 years. RESULTS: A total of 50 patients with BTAI were enrolled in the TRANSFIX study between January 2013 and May 2014. Mean follow-up was 21 months (range, 0.6-35 months). The 30-day mortality was 2% (n = 1), and it was unrelated to the aortic repair or study device. Five deaths occurred after 30 days, and one was considered procedure related. Freedom from all-cause and BTAI-related mortality was 89.3% and 97.6%, respectively, at 2 years. Aortic injury healing was noted in 96% at 2 years. An incidental finding of thrombus formation within the stent graft, most commonly at the distal aspect of the study device, occurred in 15 patients (30%; 12 by core laboratory, 3 by site) and was confirmed in 13 patients (26%). None of these patients were noted to have clinical sequelae on most recent follow-up. CONCLUSIONS: The updated results from the TRANSFIX study continue to show low rates of aortic injury-related mortality and major adverse events during follow-up. However, findings of in-graft thrombus have resulted in the manufacturer's voluntary removal of the BTAI indication for this device. Caution should be exercised in appropriate and accurate device sizing and planning (eg, limiting graft oversizing) as well as in regular, lifelong follow-up evaluation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Starnes BW, Dwivedi A, Giglia J, et al. Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device. J Vasc Surg. 2020. PMID: 32014287. doi:10.1016/j.jvs.2019.05.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。